A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

Figure 1. A 74-y-old man at initial staging with PSMA PET that demonstrates low uptake in primary tumor (A, arrowhead) and left pelvic side wall node (A, arrow). Bone scan was read as positive by 2 of ...

Health-related quality of life after IMRT or IMRT+ HDR brachytherapy for intermediate or high-risk prostate cancer: Five-year results of a prospective trial. This is an ASCO Meeting Abstract from the ...

Adverse Effects of Robotic-Assisted Laparoscopic Versus Open Retropubic Radical Prostatectomy Among a Nationwide Random Sample of Medicare-Age Men There is currently no imaging biomarker for ...

In a recent study published in Scientific Reports, a group of researchers investigated the differences in prostate magnetic resonance imaging (MRI) findings and clinical characteristics between ...

Extremely low rates of testing of bone mineral density (BMD), as recommended by recent guidelines, were found in a nationwide study of older men receiving androgen deprivation therapy (ADT) for the ...

Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...

The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation by Dr. Jozefina Casuscelli discussing the optimal management of de-novo ...